LumiraDx Limited (LMDX)

NASDAQ: LMDX · IEX Real-Time Price · USD
-0.03 (-0.76%)
May 27, 2022 4:00 PM EDT - Market closed

Company Description

LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity.

We currently have four tests available on our Platform and a broad menu of tests in development. Our proprietary Platform is designed to simplify, scale down, and integrate multiple testing methodologies onto a single instrument and offer a broad menu of tests with lab-comparable performance at a low cost and with results generally in 10 minutes or less from sample to result.

Our goal is to address the key challenges faced by healthcare providers in providing efficient and cost-effective patient care in a community setting.

In response to the COVID-19 pandemic and the resulting acute need for timely diagnostic information, we have developed our SARS-CoV-2 antigen and SARS-CoV-2 antibody tests for use in community-based healthcare settings.

As of December 31, 2020, we have placed more than 7,000 Instruments with over 500 customers across more than 25 countries and have more than 1,000 staff across the globe.

LumiraDx Limited
CountryUnited States
IndustryDiagnostics & Research
SectorHealth Care
CEORon Zwanziger

Contact Details

221 Crescent Street. 5th Floor
Waltham, MA 02453
United States
Phone44 11 7284 2535

Stock Details

Ticker SymbolLMDX
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1685428

Key Executives

Ron ZwanzigerChief Executive Officer, Co-Founder and Chairman
Dr. David Scott Ph.D.Chief Technology Officer, Co-Founder and Director
Dr. Jerome F. McAleerChief Scientist, Co-Founder and Director
Dorian LeBlanc CPAChief Financial Officer and Vice President of Global Operations
Veronique AmeyeExecutive Vice President and General Counsel
Colleen McMillenVice President of Communications
Andy WardNational Sales Director - UK
Peter ScheuPresident of North American Commercial Operations
David WaltonChief Commercial Officer
Dr. Nigel LindnerChief Innovation Officer

Latest SEC Filings

May 12, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 11, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
May 2, 2022S-8Securities to be offered to employees in employee benefit plans
May 2, 2022F-1Registration statement for certain foreign private issuers
Apr 27, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Apr 13, 202220-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]
Mar 10, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 9, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 3, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Mar 1, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings